Safinamide
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 133865-89-1 |
| ATC code | None |
| PubChem | CID 131682 |
| ChemSpider | 116349  |
| UNII | 90ENL74SIG  Category:Articles with changed FDA identifier |
| ChEMBL | CHEMBL396778 |
| Synonyms | (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl] methylamino]propanamide |
| Chemical data | |
| Formula | C17H19FN2O2 |
| Mol. mass | 302.34 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Safinamide is a candidate drug against Parkinson's disease with multiple methods of action.[1] In 2007, a Phase III clinical trial was started. It is scheduled to run until 2011.[2] The drug will be marketed by Merck-Serono.
Possible additional uses are restless legs syndrome (RLS) and epilepsy.[3] As of 2008[update], they are in Phase II.
Contents |
[edit] Methods of action
[edit] Parkinson and RLS relevant mechanisms
Safinamide is a monoamine oxidase B inhibitor, reducing degradation of dopamine.
It is a glutamate release inhibitor.
It seems to inhibit dopamine reuptake.
[edit] Other mechanisms
Furthermore, safinamide blocks sodium and calcium channels.
[edit] References
- ^ Fariello, RG (2007). "Safinamide". Neurotherapeutics 4 (1): 110–116. doi:10.1016/j.nurt.2006.11.011. PMID 17199024.
- ^ Study of Safinamide in Early Parkinson's Disease as Add-on to Dopamine Agonist (MOTION)
- ^ Chazot, PL (2007). "Drug evaluation: Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome". Current opinion in investigational drugs 8 (7): 570–579. PMID 17659477.
